epiSUMMARY

Manitoba Monthly Surveillance Report

August 2014

Reportable Diseases	Mo	nthly Cases	Monthly Rate (95%)	Current Month Cases by RHA						Year-to-Date Cases			
Disease or Organism Name	Current	3-Year-Average	Current	3-Year-Average	WRHA	IERHA	NRHA	РМН	SH	Unk	2014	2013	Change
Enterics													
HEPATITIS A	1	1	0.8 (0.0-4.3)	0.8 (0.0-4.4)	0	0	0	1	0	0	7	7	0
AMEBIASIS	2	2	1.6 (0.2-5.6)	1.6 (0.2-5.7)	2	0	0	0	0	0	17	14	3
E. COLI-VEROTOXIGENIC	3	4	2.3 (0.5-6.8)	3.1 (0.9-8.1)	1	0	0	0	2	0	29	20	9
SHIGELLOSIS	3	4	2.3 (0.5-6.8)	3.1 (0.9-8.1)	3	0	0	0	0	0	23	19	4
CRYPTOSPORIDIOSIS	22	5	17.1 (10.7-25.8)*	3.9 (1.3-9.2)	6	2	6	4	4	0	51	16	35
GIARDIASIS	6	15	4.7 (1.7-10.1)	11.8 (6.6-19.5)	4	0	2	0	0	0	54	73	-19
SALMONELLOSIS	16	18	12.4 (7.1-20.2)	14.2 (8.4-22.4)	8	0	0	2	6	0	152	146	6
CAMPYLOBACTER	25	39	19.4 (12.5-28.6)	30.7 (21.8-42.0)	7	3	2	6	7	0	116	152	-36
VPD													
PNEUMOCOCCAL INVASIVE DISEASE	3	9	2.3 (0.5-6.8)	7.1 (3.2-13.4)	3	0	0	0	0	0	87	97	-10
Respiratory Diseases and TB													
TB (DATA NOT AVAILABLE)													
EMD and Zoonotics													
TULAREMIA	1	0	0.8 (0.0-4.3)	0.0 (0.0-2.9)	1	0	0	0	0	0	2	4	-2
MALARIA	4	1	3.1 (0.8-7.9)	0.8 (0.0-4.4)	4	0	0	0	0	0	15	10	5





Reportable Diseases	Mo	nthly Cases	Monthly Rate (95%CI) (Per 1,000,000)			Current Month Cases by RHA							Year-to-Date Cases			
Disease or Organism Name	Current	3-Year-Average	Cı	urrent	3-Yea	ar-Average	WRHA	IERHA	NRHA	РМН	SH	Unk	2014	2013	Change	
LYME DISEASE	1	2	0.8	(0.0-4.3)	1.6	(0.2-5.7)	0	0	0	0	1	0	10	14	-4	
BLASTOMYCOSIS	2	2	1.6	(0.2-5.6)	1.6	(0.2-5.7)	1	0	0	0	1	0	8	13	-5	
STRONGYLOIDES	2	3	1.6	(0.2-5.6)	2.4	(0.5-6.9)	2	0	0	0	0	0	17	16	1	
WNV NEUROLOGICAL SYNDROME	1	2	0.8	(0.0-4.3)	1.6	(0.2-5.7)	1	0	0	0	0	0	1	1	0	
Non VPD																
STREP. TOXIC SHOCK SYNDROME	2	0	1.6	(0.2-5.6)	0.0	(0.0-2.9)	1	0	0	1	0	0	2	3	-1	
NECROTIZING FASCIITIS (STREP.)	1	1	0.8	(0.0-4.3)	0.8	(0.0-4.4)	0	0	1	0	0	0	4	15	-11	
STREP. INVASIVE DISEASE	23	30	17.8	(11.3-26.8)	23.6	(15.9-33.7)	14	3	3	1	2	0	192	206	-14	
ARO and Nosocomial Organisms																
CLOSTRIDIUM DIFFICILE	61	61	47.3	(36.2-60.8)	48.0	(36.7-61.7)	40	4	2	4	11	0	564	577	-13	
(DATA NOT AVAILABLE FOR THE OTHER)																
STBBI																
HEPATITIS B*	2	1	1.6	(0.2-5.6)	0.8	(0.0-4.4)	0	0	0	0	2	0	4	6	-2	
HIV	10	8	7.8	(3.7-14.3)	6.3	(2.7-12.4)	7	1	0	0	2	0	61	79	-18	
SYPHILIS (Sero-reactive)*	15		11.6	(6.5-19.2)			12	1	1	1	0	0	283	155	128	
HEPATITIS C	34	26	26.4	(18.3-36.9)	20.5	(13.4-30.0)	26	1	3	3	1	0	243	210	33	
GONORRHEA	92	112	71.4	(57.5-87.5)	88.2	(72.6-106.1)	43	13	27	6	3	0	683	828	-145	
CHLAMYDIA	483	559	374.6	(342.0-409.6)	440.0	(404.3-478.1)	236	44	109	58	36	0	4111	4275	-164	





Data extracted: October 15, 2014

Notes and Abbreviations

Notes:

- 1. 3-year-average cases / rate are defined as the average cases / rate reported in the same month over the previous three years.
- 2. Out-of-province cases are excluded.
- 3. The diseases where the current monthly rates are significantly higher than the previous 3-year average rates for the same month are highlighted yellow.
- 4. Syphilis: Due to improved testing and referral processes that took place in 2013, there was an observed increase in the number of records entered into the surveillance system. The data point shown in the table includes all reported Treponema serology-reactive individuals, however these may be infectious and non-infectious cases, as well as those requiring further public health follow-up to determine this status. These factors also make it difficult to draw a comparison to historical data, therefore statistical testing was not done.
- 5. Hepatitis B: This includes confirmed cases of acute infection only, where both surface antigen (HBsAG) and core antibody (Anti-HBc IgM) are positive.

Abbreviations:

ARO Antibiotic Resistant Organisms

CI Confidence Interval

EMD Environmentally Mediated Diseases

IERHA Interlake-Eastern Regional Health Authority MRSA Methicillin Resistant Staphylococcus Aureus

NRHA Northern Regional Health Authority

PMH Prairie Mountain Health RHA Regional Health Authority

STBBI Sexually Transmitted & Blood-Borne Infections

TB Tuberculosis

VPD Vaccine Preventable Diseases

VRE Vanocomycin-Resistant Enterococci

VRSA Vancomycin Resistan Staphylococcus Aureus

WNV West Nile Virus

WRHA Winnipeg Regional Health Authority

